Hong Kong (HSI) Healthcare Services Industry Analysis

Industry Valuation and Performance

Has the Hong Kong Healthcare Services Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sun, 07 Jun 2026	HK$144.7b	HK$787.2b	HK$10.8b	13.2x	13.4x	0.2x
Tue, 05 May 2026	HK$173.2b	HK$780.1b	HK$10.7b	15.1x	16.2x	0.2x
Thu, 02 Apr 2026	HK$219.7b	HK$774.1b	HK$9.5b	13.5x	23.1x	0.3x
Sat, 28 Feb 2026	HK$158.9b	HK$770.9b	HK$9.4b	11.3x	16.9x	0.2x
Mon, 26 Jan 2026	HK$161.0b	HK$758.5b	HK$9.2b	12x	17.5x	0.2x
Wed, 24 Dec 2025	HK$156.5b	HK$749.9b	HK$9.1b	12.2x	17.2x	0.2x
Fri, 21 Nov 2025	HK$172.5b	HK$738.6b	HK$8.9b	12.9x	19.3x	0.2x
Sun, 19 Oct 2025	HK$178.6b	HK$738.2b	HK$8.3b	12.7x	21.6x	0.2x
Tue, 16 Sep 2025	HK$235.8b	HK$822.8b	HK$11.4b	13.5x	20.6x	0.3x
Thu, 14 Aug 2025	HK$234.0b	HK$827.1b	HK$13.0b	13.9x	18x	0.3x
Sat, 12 Jul 2025	HK$216.2b	HK$827.2b	HK$13.0b	13.1x	16.7x	0.3x
Mon, 09 Jun 2025	HK$236.3b	HK$808.8b	HK$10.8b	13x	21.9x	0.3x
Wed, 07 May 2025	HK$209.0b	HK$796.4b	HK$10.4b	10.8x	20.1x	0.3x
Fri, 04 Apr 2025	HK$216.9b	HK$798.1b	HK$10.4b	12.8x	20.8x	0.3x
Sun, 02 Mar 2025	HK$203.6b	HK$806.5b	HK$14.5b	12.6x	14x	0.3x
Tue, 28 Jan 2025	HK$199.6b	HK$811.1b	HK$14.6b	12.7x	13.7x	0.2x
Thu, 26 Dec 2024	HK$224.9b	HK$804.0b	HK$14.5b	12.1x	15.5x	0.3x
Sat, 23 Nov 2024	HK$216.3b	HK$811.3b	HK$14.6b	13x	14.8x	0.3x
Mon, 21 Oct 2024	HK$219.9b	HK$826.6b	HK$15.3b	13x	14.4x	0.3x
Wed, 18 Sep 2024	HK$195.3b	HK$836.7b	HK$15.6b	13x	12.5x	0.2x
Fri, 16 Aug 2024	HK$226.8b	HK$829.3b	HK$12.7b	10.8x	17.9x	0.3x
Sun, 14 Jul 2024	HK$242.1b	HK$820.2b	HK$12.5b	10.8x	19.4x	0.3x
Tue, 11 Jun 2024	HK$264.6b	HK$822.5b	HK$12.6b	12.5x	21.1x	0.3x
Thu, 09 May 2024	HK$255.4b	HK$824.5b	HK$12.6b	12.3x	20.3x	0.3x
Sat, 06 Apr 2024	HK$223.7b	HK$821.4b	HK$12.7b	11.5x	17.6x	0.3x
Mon, 04 Mar 2024	HK$248.3b	HK$814.9b	HK$11.8b	14.3x	21.1x	0.3x
Wed, 31 Jan 2024	HK$230.3b	HK$825.4b	HK$12.1b	15.1x	19x	0.3x
Fri, 29 Dec 2023	HK$242.8b	HK$824.6b	HK$12.5b	15.3x	19.4x	0.3x
Sun, 26 Nov 2023	HK$262.6b	HK$816.8b	HK$12.3b	15.3x	21.3x	0.3x
Tue, 24 Oct 2023	HK$268.0b	HK$801.5b	HK$12.3b	13.2x	21.8x	0.3x
Thu, 21 Sep 2023	HK$290.5b	HK$804.0b	HK$12.7b	12.6x	22.9x	0.4x
Sat, 19 Aug 2023	HK$289.4b	HK$776.4b	HK$8.6b	11.6x	33.7x	0.4x
Mon, 17 Jul 2023	HK$327.3b	HK$810.6b	-HK$34,336,153.00	11.3x	-9532.1x	0.4x
Wed, 14 Jun 2023	HK$312.4b	HK$772.4b	HK$632.2m	13.2x	494.2x	0.4x

Current Industry PE

Investors are pessimistic on the Hong Kong Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 13.4x which is higher than its 3-year average PE of -59.0x.

The industry is trading close to its 3-year average PS ratio of 0.28x.

Past Earnings Growth

The earnings for companies in the Healthcare industry have grown 157% per year over the last three years, while revenues have remained mostly flat.
This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the Hong Kong Healthcare industry?


HK Market	-0.88%
Healthcare	-7.81%
Healthcare Services	-3.12%
Managed Healthcare	0%	0
Healthcare Distributors	-0.15%
Healthcare Facilities	-1.74%
Healthcare Services	-8.29%

Industry PE

Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio.

Analysts are expecting annual earnings growth of 35.9%, which is higher than its past year's earnings decline of 30.1% per year.

Investors are most pessimistic about the Healthcare Distributors industry, which is trading below its 3-year average of 12.2x.

Forecasted Growth

Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 36% over the next 5 years.
This is better than its past earnings decline of 30% per year.

In contrast, the Healthcare Distributors industry is expected to see its earnings grow by 9.0% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
1099 Sinopharm Group	HK$17.21	1.7% +HK$905.0m	-7.9%	PE6.5x
2677 Distinct Healthcare Holdings	HK$24.94	15.1% +HK$211.8m	n/a	PE10.3x
2609 Bayzed Health Group	HK$5.00	1.4% +HK$92.3m	n/a	PS5.1x
2666 Genertec Universal Medical Group	HK$5.21	0.8% +HK$80.6m	-3.5%	PE4.2x
1951 Jinxin Fertility Group	HK$2.27	1.3% +HK$80.1m	-23.1%	PS2x

Company

Last Price

Valuation

1099 Sinopharm Group

HK$17.21

1.7%
+HK$905.0m

-7.9%

PE6.5x

2677 Distinct Healthcare Holdings

HK$24.94

15.1%
+HK$211.8m

n/a

PE10.3x

2609 Bayzed Health Group

HK$5.00

1.4%
+HK$92.3m

n/a

PS5.1x

2666 Genertec Universal Medical Group

HK$5.21

0.8%
+HK$80.6m

-3.5%

PE4.2x

1951 Jinxin Fertility Group

HK$2.27

1.3%
+HK$80.1m

-23.1%

PS2x

Qingsong Health Corporation Announces Integration of QSevidence into QSmedical Platform

QingSong Health Corporation announced that the Group’s self-developed AI evidence-based medical agent product “QSevidence” has been officially embedded into the Group’s platform “QSmedical”, which provides professional services to physicians and medical professionals, achieving a product-level integration of the Group’s self-developed medical AI capabilities with its proprietary physician service network. “QSevidence” is an evidence-based medical agent designed around evidence-based methodology. Tailored for real clinical scenarios, it provides physicians with interpretable, verifiable, and traceable medical decision support, elevating AI from a “medical question-answering tool” to an “evidence-based decision assistant”. According to the Group’s internal statistics as of March 31, 2026, the number of medical professional users on the “QSmedical” platform empowered by “QSevidence” reached 69,615, representing a 46.4% increase from 47,554 as of March 31, 2025. The number of ophthalmology medical professional users reached 3,672, representing a 171.0% increase from 1,355 as of March 31, 2025. The number of physicians at or above the level of associate chief physician reached 36,678 (accounting for approximately 52.7% of the total medical professional users on the platform), representing a 42.7% increase from 25,701 as of March 31, 2025. The embedding of “QSevidence” into “QSmedical” marks the formation of a synergistic framework combining the Group’s self-developed evidence-based medical AI capabilities with its large-scale physician service network, enabling evidence-based AI capabilities to directly serve the clinical decision-making and professional development needs of frontline medical professionals. The continuous expansion of the platform’s medical professional user base, particularly the fact that physicians at or above the level of associate chief physician account for more than half, reflects the user structure and professional depth of the Group’s digital services for medical professionals. The above progress has laid a foundation for the Group’s continued development in the areas of evidence-based medical assistance, digital services for medical professionals, and AI-driven professional healthcare intelligent services. The Company has formed a three-tier progressive AI strategy based on its self-developed AIcare technology stack: Infrastructure Foundation: i-DataCloud, providing AI infrastructure capabilities for all business scenarios; Core Model: Dr.GPT vertical medical large model, supporting the intelligence of the entire ecosystem of healthcare services; Vertical Agent Applications: QSevidence series of evidence-based medical agent products, focusing on evidence-based medical scenarios for professional physicians, extending the Group’s AI capabilities from general healthcare services to serious medical domains. Leveraging the core technological advantages of the AIcare technology stack, the Group will continue to focus on vertical scenarios in the medical and healthcare field. It will deepen the development and deployment of AI agents in areas such as evidence-based medicine, clinical decision-making, physician services, and public health management. The Group aims to build a full-chain AI service matrix covering both professional and user sides, while advancing the digital and intelligent upgrade of medical and healthcare services, thereby injecting momentum into the Group’s long-term high-quality development.

Hong Kong (HSI) Healthcare Services Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Investor sentiment improves as stock rises 15%

Genertec Universal Medical Group Company Limited, Annual General Meeting, Jun 24, 2026

Now 27% undervalued after recent price drop

ADICON Holdings Limited Announces Yeh Richard as the Lead Independent Non-Executive Director, Effective May 27, 2026

value + defensive emerging markets healthcare

Upcoming dividend of HK$0.086 per share

Gushengtang Holdings (HKG:2273) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Chairman & Co-CEO recently bought HK$3.0m worth of stock

Now 23% undervalued

Dividend increased to HK$0.0018

Qingsong Health Corporation Announces Integration of QSevidence into QSmedical Platform

Full year 2025 earnings: EPS and revenues miss analyst expectations

Jiangxi Rimag Group Co., Ltd. Appoints Meng Tao as Non-Executive Director and Member of the Audit Committee, Effective from 23 April 2026

Full year 2025 earnings released: CN¥0.032 loss per share (vs CN¥0.018 profit in FY 2024)

New major risk - Market cap size

Full year 2025 earnings released: CN¥0.24 loss per share (vs CN¥0.37 loss in FY 2024)